Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.81 |
| ▸ | ADORA2B | P29275 | 19/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510788 | 0.89 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6509342 | 0.77 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6511601 | 0.77 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6508771 | 0.76 | ADORA2A (0.76) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6506369 | 0.74 | ADORA2B (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL6512612 | 0.73 | ADORA2A (0.84) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6509136 | 0.73 | ADORA2B (1.00) | ADORA2AADORA2B | |
| SCHEMBL6529603 | 0.73 | ADORA2A (0.70) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6529602 | 0.73 | ADORA2A (0.70) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6504543 | 0.72 | ADORA2B (0.84) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | disclosed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | ADORA2A 2/4885ADORA2B 4/4885ADORA1 1/4885 |
| US-20050192339-A1 | Compounds | MCHR1, HCRTR1, NPY1R | ADORA2A 228/4885ADORA2B 205/4885ADORA1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.